Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Masimo Corporation

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report), Bristol-Myers Squibb (BMY – Rese...

Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ)

Masimo ( ($MASI) ) has provided an update. On December 1, 2025, Masimo Corporation successfully refinanced its credit obligations by terminating it...

Masimo Secures New $1 Billion Credit Facility

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Masimo, with a price target of $210.00. Bednar covers the He...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MASI	$140.41	+0.45%	861.60K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MASI	$140.41	+0.5%	861.60K
3
4
5
6

MASI

MASI

Latest News for MASI

Get Masimo Corporation Data in Excel

Get Masimo Corporation Data in Excel